COO
The Cooper Companies, Inc.
COO has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over COO overall, supported by stronger fundamentals.
COO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
COO's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
COO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $62.19 | — |
| Cheap | 17x | $50.37 | -19% |
| Current | 21x | $62.19 | — |
| Fair | 40x | $117 | +89% |
| Expensive | 61x | $179 | +189% |
Historical ranges are pointers, not guarantees.
COO's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 13x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over COO in the historical PE scenario, which offers more potential upside but is not a forecast.
COO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect COO's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over COO on the outlook, with more favorable revenue expectations.
COO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.64 | +59% |
| Q3 2026 | $2.92 | +43% |
| Q2 2026 | $1.17 | -43% |
| Q1 2026 | $2.01 | -2.9% |
| Q4 2025 | $1.87 | -4.6% |
| Q3 2025 | $2.04 | +14% |
| Q2 2025 | $2.07 | +22% |
| Q1 2025 | $2.07 | +42% |
| Q4 2024 | $1.96 | +32% |
COO has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
COO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +0.6% |
| Q2 2026 | $1.1B | +7.9% |
| Q1 2026 | $1B | +6.2% |
| Q4 2025 | $1.1B | +4.6% |
| Q3 2025 | $1.1B | +5.7% |
| Q2 2025 | $1B | +6.3% |
| Q1 2025 | $964.7M | +3.6% |
| Q4 2024 | $1B | +9.8% |
COO's revenue has grown year over year for 23 quarters in a row: $1.1B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +4.3 points |
| Q2 2026 | -2.9% | -21 points |
| Q1 2026 | 21% | +1.9 points |
| Q4 2025 | 13% | -6.3 points |
| Q3 2025 | 17% | -2.6 points |
| Q2 2025 | 18% | +1.3 points |
| Q1 2025 | 19% | +2.4 points |
| Q4 2024 | 19% | +4.8 points |
COO has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over COO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
COO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $273M | +66% |
| Q2 2026 | $96.4M | +433% |
| Q1 2026 | $158.7M | +57% |
| Q4 2025 | $149.9M | +17% |
| Q3 2025 | $164.5M | +39% |
| Q2 2025 | $18.1M | -51% |
| Q1 2025 | $101.2M | +2100% |
| Q4 2024 | $128.1M | +339% |
COO has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
COO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -1.6M shares |
| 1 year | -3.3% | -6.6M shares |
| 3 years | -3.1% | -6.2M shares |
| 5 years | -2.9% | -5.8M shares |
| Available history | -3.3% | -6.6M shares |
COO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $339.2M |
| Q2 2026 | $15.5M |
| Q1 2026 | $92.5M |
| Q4 2025 | $196.8M |
| Q3 2025 | $52.7M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
COO spent $644M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
COO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.6x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.2x | Moderate |
| Q4 2024 | 2.3x | Moderate |
COO's net debt is about 2.6 years of its operating earnings (EBITDA), up from 2.1 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over COO on leverage, with a lower net debt burden relative to earnings.
COO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.3 | Neutral |
| Stochastic | 38.2 | Neutral |
COO's weekly RSI is 46 (neutral) and its Stochastic is 38 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
COO PE vs Healthcare Sector
| Metric | COO | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 18% below |
| PE % | 22 | 29 | 7 pts below |
COO is trading at 21x earnings, a 18% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over COO on valuation relative to its sector.
COO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $58.7 | 5.9% above |
| 20 week MA | $65.3 | 4.7% below |
| 50 week MA | $70.3 | 12% below |
| 100 week MA | $74.3 | 16% below |
| 200 week MA | $83.9 | 26% below |
COO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 26% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over COO on trend strength, trading above more of its moving averages.
COO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $80.3 | $89.6 | +12% |
| 2021 | $89.6 | $102.8 | +15% |
| 2022 | $102.8 | $83.2 | -19% |
| 2023 | $83.2 | $94.6 | +14% |
| 2024 | $94.6 | $92.3 | -2.4% |
| 2025 | $92.3 | $82.6 | -11% |
| 2026 YTD | $82.6 | $62.2 | -25% |
COO has finished lower in three of the last six years. It's down 25% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over COO on returns for 2026, with the stronger performance.